Drug Trial Radar · NCT06924970
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
59
Actual
Start
May 1, 2025
Primary completion
May 12, 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Conditions
- Sickle Cell Disease
Interventions
TebapivatDrug
Oral tablets.
Tebapivat Matched PlaceboDrug
Oral tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Hb ResponseTime frame: Baseline, Week 10 through Week 12
Locations
20 sites in 7 countries. Site status is shown where the registry gives one.
UConn Health
Farmington, Connecticut
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
Atlanta, Georgia
Henry Ford Health System
Detroit, Michigan
Children's Hospital of Michigan
Detroit, Michigan
Icahn School of Medicine at Mt. Sinai
New York, New York
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Prisma Health Cancer Institute - Farris Road
Greenville, South Carolina
University of Texas Health Science Center of Houston
Houston, Texas
Fred Hutchinson Cancer Center, University of Washington
Seattle, Washington
CHR de la Citadelle
Liège, Wallonne, Belgium
CHU Montreal
Montreal, Quebec, Canada
Hôpital Edouard Herriot, CHU de Lyon
Lyon, Auvergne-Rhône-Alpes, France
CHU Hôpital Henri Mondor
Créteil, Île-de-France Region, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, Midi Pyrenees, France
St. James Hospital
Dublin, Leinster, Ireland
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands
Amsterdam Universitair Medisch Centrum, Locatie AMC
Amsterdam, North Holland, Netherlands
Erasmus MC
Rotterdam, South Holland, Netherlands
University College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.